
THIS SUPPLEMENTAL CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this supplemental circular or as to the action to be taken, you should consult a stockbroker or other registered dealer in securities, a bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in AK Medical Holdings Limited, you should at once hand this supplemental circular, together with the enclosed second form of proxy, to the purchaser or transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this supplemental circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this supplemental circular.



AK MEDICAL HOLDINGS LIMITED

愛康醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1789)

**SUPPLEMENTAL CIRCULAR
IN RELATION TO THE RE-ELECTION OF DIRECTOR
AND
SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING**

This supplemental circular should be read together with the circular of AK Medical Holdings Limited dated 29 April 2021 and the notice dated 29 April 2021 convening an annual general meeting of the Company to be held at 2/F Xing Ye Building, No. 10 Baifuquan Road, Changping Science & Technology Park District, Beijing, China on Tuesday, 15 June 2021 at 10:00 a.m. A supplemental notice of the annual general meeting of the Company is set out on page 9 of this supplemental circular. A second proxy form for the annual general meeting, which shall supersede the form of proxy enclosed with the circular dated 29 April 2021, is also enclosed.

Whether or not you are able to attend the annual general meeting, please complete and sign the enclosed second form of proxy for use at the annual general meeting in accordance with the instructions printed thereon and return it to the Company's branch share registrar in Hong Kong, Tricor Investor Services Limited, at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong as soon as possible but in any event not less than 48 hours before the time appointed for the Annual General Meeting (i.e. not later than 10:00 a.m. on Sunday, 13 June 2021) or the adjourned meeting (as the case may be). Completion and return of the second form of proxy will not preclude shareholders from attending and voting in person at the annual general meeting if they so wish.

This supplemental circular together with the second form of proxy are also published on the websites of Hong Kong Exchanges and Clearing Limited (<http://www.hkexnews.hk>) and the Company (<http://www.ak-medical.net>).

References to time and dates in this supplemental circular are to Hong Kong time and dates.

28 May 2021

CONTENTS

	<i>Page</i>
Definitions	1
Letter from the Board	
1. Introduction	3
2. Proposed Re-election of Additional Retiring Director	4
3. Supplemental Notice of Annual General Meeting and Second Proxy Form	4-5
4. Recommendation	5
Appendix I – Details of the Additional Retiring Director Proposed to be Re-elected at the Annual General Meeting	7-8
Supplemental Notice of Annual General Meeting	9

DEFINITIONS

In this supplemental circular, unless the context otherwise requires, the following expressions shall have the following meanings:

“Annual General Meeting”	the annual general meeting of the Company to be held at 2/F Xing Ye Building, No. 10 Baifuquan Road, Changping Science & Technology Park District, Beijing, China on Tuesday, 15 June 2021 at 10:00 a.m., any adjournment thereof
“Articles of Association”	the second amended and restated articles of association of the Company (as amended from time to time)
“Board”	the board of Directors
“China” or “the PRC”	the People’s Republic of China excluding, for the purpose of this supplemental circular, Hong Kong, the Macau Special Administrative Region of China and Taiwan
“Circular”	the circular of the Company dated 29 April 2021
“Company”	AK Medical Holdings Limited, a company incorporated in the Cayman Islands with limited liability, the Shares of which are listed on the Main Board of the Stock Exchange
“Director(s)”	the director(s) of the Company
“First Proxy Form”	the form of proxy sent together with the Circular
“Group”	the Company and its subsidiaries
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Latest Practicable Date”	21 May 2021, being the latest practicable date prior to the printing of this supplemental circular for ascertaining certain information in this supplemental circular
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange as amended from time to time
“Second Proxy Form”	the second form of proxy sent together with this supplemental circular
“SFO”	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)

DEFINITIONS

“Share(s)”	ordinary share(s) of HK\$0.01 each in the issued capital of the Company
“Shareholder(s)”	holder(s) of Share(s)

LETTER FROM THE BOARD



AK MEDICAL HOLDINGS LIMITED

愛康醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1789)

Executive Directors:

Mr. Li Zhijiang
Ms. Zhang Bin
Mr. Zhang Chaoyang
Ms. Zhao Xiaohong

Registered Office:

Conyers Trust Company (Cayman) Limited
Cricket Square, Hutchins Drive
PO Box 2681, Grand Cayman
KY1-1111, Cayman Islands

Non-executive Director:

Dr. Wang David Guowei

Headquarters and Principal

Place of Business in China:

2/F, Xingye Building
10 Baifuquan Road
Changping District Science
and Technology Park
Beijing
China

Independent Non-executive Directors:

Mr. Kong Chi Mo
Dr. Li Shu Wing David
Mr. Eric Wang

*Principal Place of Business
in Hong Kong:*

Level 54, Hopewell Centre
183 Queen's Road East
Hong Kong

28 May 2021

To the Shareholders

Dear Sir/Madam,

**SUPPLEMENTAL CIRCULAR
IN RELATION TO THE RE-ELECTION OF DIRECTOR
AND
SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING**

1. INTRODUCTION

This supplemental circular should be read together with the Circular which contains, inter alia, the notice of the Annual General Meeting and information relating to the re-election of retiring Directors at the Annual General Meeting.

The purpose of this supplemental circular is to provide you with further information in respect of the resolution to be proposed at the Annual General Meeting for the re-election of an additional retiring Director and to give you a supplemental notice of the Annual General Meeting and the Second Proxy Form.

LETTER FROM THE BOARD

2. PROPOSED RE-ELECTION OF ADDITIONAL RETIRING DIRECTOR

Subsequent to the despatch of the Circular and the notice of Annual General Meeting, the Board discussed with Dr. Wang David Guowei (“**Dr. Wang**”), a non-executive Director who initially decided to retire and not to offer himself for re-election and reappointment at the Annual General Meeting, and expressed its appreciation to Dr. Wang for his valuable efforts and contributions to the Company. Dr. Wang would now agree to offer himself for re-election and reappointment as non-executive Director at the Annual General Meeting.

As a result, there are four retiring Directors standing for re-election as Directors at the Annual General Meeting, namely Mr. Li Zhijiang, Ms. Zhang Bin, Mr. Eric Wang and Dr. Wang. The resolution relating to the re-election of Dr. Wang as non-executive Director will be set out in the supplemental notice of Annual General Meeting.

The biographical details of Dr. Wang is set out in Appendix I to this supplemental circular.

3. SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING AND SECOND PROXY FORM

Since the notice of the Annual General Meeting and the First Proxy Form sent together with the Circular do not contain the proposed resolution for the re-election of Dr. Wang as non-executive Director as set out in this supplemental circular, a supplemental notice of Annual General Meeting has been set out on page 9 of this supplemental circular and the Second Proxy Form is enclosed with this supplemental circular to include such proposed resolution. Pursuant to the Listing Rules and the Articles of Association, any vote of Shareholders at a general meeting must be taken by poll except where the chairman decides to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands. An announcement on the poll results will be published by the Company after the Annual General Meeting in the manner prescribed under the Listing Rules.

The Second Proxy Form for use at the Annual General Meeting is enclosed with this supplemental circular and the Second Proxy Form is also published on the websites of Hong Kong Exchanges and Clearing Limited (<http://www.hkexnews.hk>) and the Company (<http://www.ak-medical.net>). To be valid, the Second Proxy Form must be completed and signed in accordance with the instructions printed thereon and deposited, together with the power of attorney or other authority (if any) under which it is signed or a certified copy of that power of attorney or authority at the Company’s branch share registrar in Hong Kong, Tricor Investor Services Limited, at Level 54, Hopewell Centre, 183 Queen’s Road East, Hong Kong as soon as possible but in any event not less than 48 hours before the time appointed for the Annual General Meeting (i.e. not later than 10:00 a.m. on Sunday, 13 June 2021) or the adjourned meeting (as the case may be) (the “**Closing Time**”). Completion and delivery of the Second Proxy Form will not preclude you from attending and voting at the Annual General Meeting if you so wish.

LETTER FROM THE BOARD

A Shareholder who has not yet lodged the First Proxy Form with the Company's Hong Kong branch share registrar is requested to lodge the Second Proxy Form if he/she wishes to appoint proxy(ies) to attend and vote at the Annual General Meeting on his/her behalf. In this case, the First Proxy Form should not be lodged with the Company's Hong Kong branch share registrar.

A Shareholder who has already lodged the First Proxy Form with the Company's Hong Kong branch share registrar should take note of the following:

- (i) subject to (iii) below, if no Second Proxy Form is lodged with the Company's Hong Kong branch share registrar, the First Proxy Form will be treated as a valid form of proxy lodged by him/her if correctly completed and signed. The proxy so appointed by the Shareholder shall be required to vote in such manner as he/she may be directed under the First Proxy Form and, in respect of the resolution for the proposed re-election of Dr. Wang as a non-executive Director as set out in the supplemental notice of Annual General Meeting and the Second Proxy Form, the proxy will be entitled to vote at his/her discretion or to abstain from voting on such resolution;
- (ii) if the Second Proxy Form is lodged with the Company's Hong Kong branch share registrar before the Closing Time, the Second Proxy Form, if correctly completed and signed, shall revoke and supersede the First Proxy Form previously lodged by him/her. The Second Proxy Form will be treated as a valid form of proxy lodged by the Shareholder;
- (iii) if the Second Proxy Form is lodged with the Company's Hong Kong branch share registrar after the Closing Time, or if lodged before the Closing Time but is incorrectly completed, the proxy appointment under the Second Proxy Form will be invalid. The proxy so appointed by the Shareholder under the First Proxy Form, if correctly completed, will be entitled to vote in the manner as mentioned in (i) above as if no Second Proxy Form was lodged with the Company's Hong Kong branch share registrar.

Accordingly, Shareholders are advised to complete the Second Proxy Form carefully and lodge the Second Proxy Form with the Company's Hong Kong branch share registrar before the Closing Time.

4. RECOMMENDATION

The Directors consider that the proposed re-election of Dr. Wang as non-executive Director as set out in supplemental notice of Annual General Meeting is in the best interests of the Company and the Shareholders. Accordingly, the Directors recommend the Shareholders to vote in favour of the relevant resolution to be proposed at the Annual General Meeting.

LETTER FROM THE BOARD

Shareholders are advised to read this supplemental circular together with the Circular for information relating to the voting arrangement.

Yours faithfully,
For and on behalf of the Board
AK Medical Holdings Limited
Li Zhijiang
Chairman

**APPENDIX I DETAILS OF THE ADDITIONAL DIRECTOR PROPOSED
TO BE RE-ELECTED AT THE ANNUAL GENERAL MEETING**

The following are details of the additional Director who will retire and being eligible, offer himself for re-election at the Annual General Meeting.

Dr. Wang David Guowei, Non-executive Director

Dr. Wang David Guowei, aged 59, is a non-executive Director primarily responsible for providing advice on strategy of the Group. He was appointed as a Director on 29 February 2016 and was designated as a non-executive Director on 6 April 2016. He is a member of the Audit Committee of the Company.

Dr. Wang has over 10 years of experience in the medical industry. Dr. Wang is the senior managing director of Asia at OrbiMed Advisors LLC, an investment fund with a focus on healthcare industry, where he has worked from August 2011. Dr. Wang is a director of Amoy Diagnostics Co., Ltd. (a company listed in the Shenzhen Stock Exchange, stock code: 300685) and a director of Gracell Biotechnologies Inc. (a company listed in NASDAQ, stock code: GRCL). From April 2006 to July 2011, he served as managing director at WI Harper Group, responsible for investment activities in life sciences and healthcare areas. From March 2010 to July 2012, he served on the board of directors of Edan Instruments, Inc. (a company listed in the Shenzhen Stock Exchange, stock code: 300206), a provider of advanced electronic medical equipments, where he also served on both the audit committee and strategic committee. He ceased to be a director of Suzhou Medical System Technology Co., Ltd. (a company listed in Shanghai Stock Exchange, stock code: 603990) on 6 May 2019 and a non-executive director of Union Medical Healthcare Limited (a company listed in the Hong Kong Stock Exchange, stock code: 2138) on 24 April 2020.

Dr. Wang received his doctorate in developmental biology from California Institute of Technology in June 1995. He received his bachelor degree in medicine from Beijing Medical University (北京醫科大學) (currently known as Peking University Health Science Center (北京大學醫學部)) in July 1986.

Save as disclosed above, Dr. Wang has not held any directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years.

Dr. Wang has been appointed for an initial term of three years commencing from 6 April 2019 until terminated by either party giving not less than three months' written notice to the other. He is subject to retirement and re-election at the Annual General Meeting of the Company in accordance with the Articles of Association.

Dr. Wang does not have any relationship with any Directors, senior management or substantial or controlling shareholders of the Company. In accordance with the meaning of Part XV of the SFO, as at the Latest Practicable Date, Dr. Wang was not interested or deemed to be interested in any Shares or underlying Shares of the Company or its associated corporations. Under the service contract entered into between Dr. Wang and the Company, Dr. Wang shall not receive any Director's fee.

**APPENDIX I DETAILS OF THE ADDITIONAL DIRECTOR PROPOSED
TO BE RE-ELECTED AT THE ANNUAL GENERAL MEETING**

Save as disclosed above, there is no information in relation to the re-election of Dr. Wang which is required to be disclosed pursuant to any of the requirements under Rule 13.51(2)(h) to (v) of the Listing Rules and there are no other matters in relation to the re-election of Dr. Wang that need to be brought to the attention of the Shareholders.

SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING



AK MEDICAL HOLDINGS LIMITED

愛康醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1789)

SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING

Reference is made to the notice of annual general meeting (the “**AGM Notice**”) of AK Medical Holdings Limited (the “**Company**”) dated 29 April 2021 by which the Company convenes an annual general meeting (the “**AGM**”) to be held at 2/F Xing Ye Building, No. 10 Baifuquan Road, Changping Science & Technology Park District, Beijing, China on Tuesday, 15 June 2021 at 10:00 a.m. and this supplemental notice shall be read together with the AGM Notice.

SUPPLEMENTAL NOTICE IS HEREBY GIVEN that the AGM will be as originally scheduled. In addition to the resolutions set out in the AGM Notice, the AGM will be held to consider and, if thought fit, pass the following resolution:

ORDINARY RESOLUTION

3(e). To re-elect Dr. Wang David Guowei as non-executive director of the Company.

Apart from the amendment set out above, all the information contained in the AGM Notice shall remain valid and effective.

By Order of the Board
AK Medical Holdings Limited
Li Zhijiang
Chairman

Hong Kong, 28 May 2021

Notes:

1. A second proxy form (the “**Second Proxy Form**”) is enclosed with the supplemental circular of the Company dated 28 May 2021 (the “**Supplemental Circular**”). Please refer to the section headed “Supplemental Notice of Annual General Meeting and Second Proxy Form” on pages 4 to 5 of the Supplemental Circular for the arrangements about the completion and submission of the Second Proxy Form.
2. Please refer to the AGM Notice for details of the other ordinary resolutions to be considered at AGM, closure of the register of members of the Company and eligibility for attending the AGM and other relevant matters.

As at the date of this supplemental notice, the Board comprises Mr. Li Zhijiang, Ms. Zhang Bin, Mr. Zhang Chaoyang and Ms. Zhao Xiaohong as executive directors, Dr. Wang David Guowei as non-executive director, and Mr. Kong Chi Mo, Dr. Li Shu Wing David and Mr. Eric Wang as independent non-executive directors.